Pursuing the next breakthrough

A much-anticipated clinical trial testing purified CAR-T cells manufactured at Hollings has launched, with hopes of fewer side effects and longer-lasting results.

Read about the trial
a patient sitting in a hospital bed looks up at his doctor


Facebook icon Twitter icon Instagram icon LinkedIn logo icon


Hollings researcher awarded prestigious grant to understand medulloblastoma relapse

pediatric oncology researcher Jezabel Rodriguez Blanco holds up samples to the light as student Kendell Peterson observes

One of the most prestigious pediatric cancer foundations in the U.S. has awarded Jezabel Rodriguez Blanco, Ph.D., a grant to continue her pursuit of the causes of medulloblastoma relapse. Medulloblastoma is one of the major causes of cancer-related death in children.

“Even if we believe the tumor is gone in the child after treatment, there is always the possibility of it returning at any point in their lives,” Blanco said.

Read about the grant

What’s great is now everyone can get it. Anyone can prescribe it. They don’t have to travel somewhere to get this medication. It really is a huge help for our families and kids.

Dr. Jacqueline Kraveka, pediatric cancer researcher

Read about the new drug
Jacqueline Kraveka headshot


Featured video

An ovarian cancer diagnosis was the last thing that Carol Sullivan expected. But with support from friends and family and her care team at MUSC Hollings Cancer Center, she's successfully come through treatment. Watch her inspiring story below.

Explore the News Center

Hollings Horizons Magazine   |   Media Relations   |   Cross Talk   |   Subscribe